kw.\*:("Opioid")
Results 1 to 25 of 14233
Selection :
Structure-activity relationship of rubiscolins as δ opioid peptidesSHUZHANG YANG; SONODA, Soushi; LIPING CHEN et al.Peptides (New York, NY. 1980). 2003, Vol 24, Num 4, pp 503-508, issn 0196-9781, 6 p.Article
Highly potent fluorescent analogues of the opioid peptide [Dmt1]DALDABEREZOWSKA, Irena; CHUNG, Nga N; LEMIEUX, Carole et al.Peptides (New York, NY. 1980). 2003, Vol 24, Num 8, pp 1195-1200, issn 0196-9781, 6 p.Article
Opioid peptides in cancerFICHNA, Jakub; JANECKA, Anna.Cancer metastasis reviews. 2004, Vol 23, Num 3-4, pp 351-366, issn 0167-7659, 16 p.Article
A tribute to the late Hans W. Kosterlitz : Ploughing the lone furrowLEES, G. M.Canadian journal of physiology and pharmacology. 1998, Vol 76, Num 3, pp 244-251, issn 0008-4212Article
[3H]Alvimopan binding to the μ opioid receptor : Comparative binding kinetics of opioid antagonistsCASSEL, Joel A; DAUBERT, Jeffrey D; DEHAVEN, Robert N et al.European journal of pharmacology. 2005, Vol 520, Num 1-3, pp 29-36, issn 0014-2999, 8 p.Article
Schild (apparent pA2) analysis of a κ-opioid antagonist in PlanariaRAFFA, Robert B; BARON, David A; TALLARIDA, Ronald J et al.European journal of pharmacology. 2006, Vol 540, Num 1-3, pp 200-201, issn 0014-2999, 2 p.Article
Endogenous opiates and behavior : 2004BODNAR, Richard J; KLEIN, Gad E.Peptides (New York, NY. 1980). 2005, Vol 26, Num 12, pp 2629-2711, issn 0196-9781, 83 p.Article
National Trends in the Office-Based Prescription of Schedule II OpioidsOLFSON, Mark; SHUAI WANG; IZA, Miren et al.The Journal of clinical psychiatry. 2013, Vol 74, Num 9, pp 933-940, issn 0160-6689, 8 p.Article
BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonismHUSBANDS, Stephen M; NEILAN, Claire L; BROADBEAR, Jillian et al.European journal of pharmacology. 2005, Vol 509, Num 2-3, pp 117-125, issn 0014-2999, 9 p.Article
Opioid Receptors and Their Ligands in the Musculoskeletal System and Relevance for Pain Control : Current Perspectives and Challenges in Design, Chemistry and Pharmacology of OpioidsSPETEA, Mariana.Current pharmaceutical design (Print). 2013, Vol 19, Num 42, pp 7382-7390, issn 1381-6128, 9 p.Article
75 years of opioid research : the exciting but vain quest for the Holy GrailCORBETT, Alistair D; HENDERSON, Graeme; MCKNIGHT, Alexander T et al.British journal of pharmacology. 2006, Vol 147, issn 0007-1188, S153-S162, SUP1Article
Tritiated Opioid Receptor Ligands as Radiotracers : Current Perspectives and Challenges in Design, Chemistry and Pharmacology of OpioidsTOTH, Géza; MALLAREDDY, Jayapal Reddy.Current pharmaceutical design (Print). 2013, Vol 19, Num 42, pp 7461-7472, issn 1381-6128, 12 p.Article
Non-Analgesic Effects of Opioids: Cardiovascular Effects of Opioids and their Receptor Systems : Non-Analgesic Effects of OpioidsHEADRICK, John P; PEPE, Salvatore; PEART, Jason N et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 37, pp 6090-6100, issn 1381-6128, 11 p.Article
Non-Analgesic Effects of Opioids: Factors Relevant to Opioid Abuse and Abuse-Deterrent Formulations : Non-Analgesic Effects of OpioidsPERGOLIZZI, Joseph V; RAFFA, Robert B; PERGOLIZZI, Jason S et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 37, pp 6109-6115, issn 1381-6128, 7 p.Article
Targeting of opioid-producing leukocytes for pain controlMACHELSKA, Halina.Neuropeptides (Edinburgh). 2007, Vol 41, Num 6, pp 355-363, issn 0143-4179, 9 p.Article
Increased affinity and selectivity of enkephalin tripeptide (Tyr-D-Ala-Gly) dimersLUTZ, R. A; CRUCIANI, R. A; SHIMOHIGASHI, Y et al.European journal of pharmacology. 1985, Vol 111, Num 2, pp 257-261, issn 0014-2999Article
Enkephalin degradation by enkephalinergic neuroblastoma cells: involvement of angiotensin-converting-enzymePALENKER, J; LENTZEN, H; BRANDT, U et al.Naunyn-Schmiedeberg's archives of pharmacology. 1984, Vol 325, Num 3, pp 214-217, issn 0028-1298Article
Elevation of serum corticosterone in rats by bremazocine, a κ-opioid agonistFULLER, R. W; LEANDER, J. D.Journal of pharmacy and pharmacology. 1984, Vol 36, Num 5, pp 345-346, issn 0022-3573Article
Presence of immunoreactive dynorphin in human cerebrospinal fluidTOZAWA, F; SUDA, T; TACHIBANA, S et al.Life sciences (1973). 1984, Vol 35, Num 16, pp 1633-1637, issn 0024-3205Article
The proenkephalin a fragment, peptide E: central processing and CNS activity in vivoDAVIS, T. P; PORRECA, F; BURKS, T. F et al.European journal of pharmacology. 1985, Vol 111, Num 2, pp 177-183, issn 0014-2999Article
Effects of β-endorphin fragment 6-31 on morphine- and β-endorphin-induced growth hormone and prolactin releasePANERAI, A. E; COCCHI, D; PARENTI, M et al.European journal of pharmacology. 1984, Vol 99, Num 4, pp 341-343, issn 0014-2999Article
Effects of neuroleptic treatments on peripheral opioid secretionBRAMBILLA, F; FACCHINETTI, F; PETRAGLIA, F et al.Neuropsychobiology. 1987, Vol 18, Num 2, pp 68-73, issn 0302-282XArticle
Deficit in beta-endorphin peptide and tendency to alcohol abuseZALEWSKA-KASZUBSKA, Jadwiga; CZARNECKA, Elzbieta.Peptides (New York, NY. 1980). 2005, Vol 26, Num 4, pp 701-705, issn 0196-9781, 5 p.Article
Endogenous opiates and behavior: 2006BODNAR, Richard J.Peptides (New York, NY. 1980). 2007, Vol 28, Num 12, pp 2435-2513, issn 0196-9781, 79 p.Article
4: Stimuler nos morphines internes : Vaincre la douleurDEBROISE, Anne.La Recherche (Imprimé). 2012, Num 462, pp 50-53, issn 0029-5671, 4 p.Article